Korean Center for the Validation of Alternative Methods (KoCVAM), National Institute of Food and Drug Safety Evaluation (NIFDS), Ministry of Food and Drug Safety (MFDS), 187, Osongsaengmyong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungbuk, 28157, Republic of Korea.
Korean Center for the Validation of Alternative Methods (KoCVAM), National Institute of Food and Drug Safety Evaluation (NIFDS), Ministry of Food and Drug Safety (MFDS), 187, Osongsaengmyong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungbuk, 28157, Republic of Korea.
Food Chem Toxicol. 2024 Oct;192:114942. doi: 10.1016/j.fct.2024.114942. Epub 2024 Aug 18.
With the growing importance of alternative test methods that implement the 3Rs principles (Reduction, Refinement and Replacement) and the global importance of biological safety assessment data for medical devices is increasing. We have developed and optimized the 'KeraSkin™ Skin Irritation Test (KeraSkin™ SIT) for medical device' for regulatory application in biological evaluation according to ISO 10993-23. We conducted a round robin study to optimize and evaluate the performance of KeraSkin™ SIT for medical devices using KeraSkin™ Reconstructed Human Epidermis (RhE), which is developed and manufactured in Korea. This round robin study was performed to assess the transferability, reproducibility (within and between laboratories) and predictive capacity in 1 lead laboratory and 3 participating laboratories based on OECD Guidance Document 34. The predictive capacity, the results showed 83.3 % of sensitivity, 100 % of specificity and 91.6 % of accuracy. In conclusion, the results demonstrate that 'KeraSkin™ SIT for medical device' provides a robust test method for detecting irritant activity of medical device extracts and can be utilized for identifying low levels of potent irritants in medical device extracts. Therefore, it fulfills the requirements to be included as a 'me-too' test method to EpiDerm™ and SkinEthic™ skin irritation test in ISO 10993-23.
随着越来越重视实施 3R 原则(减少、优化和替代)的替代测试方法,以及医疗器械生物安全评估数据的全球重要性不断增加,我们根据 ISO 10993-23 为医疗器械的监管应用开发和优化了“KeraSkin™皮肤刺激测试(KeraSkin™ SIT)”。我们使用在韩国开发和制造的 KeraSkin™ 重建人类表皮(RhE)进行了一项轮次间研究,以优化和评估 KeraSkin™ SIT 用于医疗器械的性能。这项轮次间研究是根据 OECD 指导文件 34 进行的,旨在评估 1 个主导实验室和 3 个参与实验室的可转移性、重现性(实验室内部和实验室之间)和预测能力。预测能力的结果表明,敏感性为 83.3%,特异性为 100%,准确性为 91.6%。总之,这些结果表明,“用于医疗器械的 KeraSkin™ SIT”为检测医疗器械提取物的刺激性活性提供了一种稳健的测试方法,可用于识别医疗器械提取物中的低水平潜在刺激性物质。因此,它符合被纳入 ISO 10993-23 中 EpiDerm™ 和 SkinEthic™ 皮肤刺激测试的“类似方法”的要求。